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Obesity is a chronic disease that negatively affects life expectancy through its association with life‑
threatening diseases such as cancer and cardiovascular diseases. Expression proteomics combined 
with in silico interaction studies are used to uncover potential biomarkers and the pathways that 
promote obesity‑related complications. These biomarkers can either aid in the development of 
personalized therapies or identify individuals at risk of developing obesity‑related diseases. To 
determine the serum protein changes, Wistar rats were fed standard chow (low fat, LF), or chow 
formulated high fat (HF) diets (HF1, HF2 and HF3) for 8 and 42 weeks to induce obesity. Serum 
samples were collected from lean and obese rats at these time points. The serum samples were 
precipitated using trichloroacetic acid (TCA)/acetone and analyzed by 2‑Dimensional SDS‑PAGE. 
Serum protein profiles were examined using mass spectrometry (MS)‑based proteomics and validated 
by western blotting. Protein–protein interactions among the selected proteins were studied in silico 
using bioinformatics tools. Several proteins showed differences in expression among the three 
HF diets when compared to the LF diet, and only proteins with ≥ twofold expression levels were 
considered differentially expressed. Apolipoprotein‑AIV (APOA4), C‑reactive protein (CRP), and alpha 
2‑HS glycoprotein (AHSG) showed differential expression at both 8 and 42 weeks, whereas alpha 1 
macroglobulin (AMBP) was differentially expressed only at 8 weeks. Network analysis revealed some 
interactions among the proteins, an indication that these proteins might interactively play a crucial 
role in development of obesity‑induced diseases. These data show the variation in the expression of 
serum proteins during acute and chronic exposure to high fat diet. Based on the expression and the 
in‑silico interaction these proteins warrant further investigation for their role in obesity development.
Abbreviations
AFP  Alpha fetoprotein
AHSG  Alpha 2-HS glycoprotein
ALB  Albumin
AMBP  Alpha 1 macroglobulin
APOA4  Apolipoprotein-AIV
CRP  C-reactive protein
CVDs  Cardiovascular diseases
DIO  Diet-induced obesity
FAs  Fatty acids
FGG  Fibrinogen gamma chain
GC–MS  Gas chromatography mass spectrometer
HF  High fat
HPX  Hemopexin
LF  Low fat
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MALDI-MS  Matrix assistant laser desorption/ionization mass spectrometry
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis
T2D  Type 2 diabetes
TCA  Trichloroacetic acid
Obesity, defined by a body mass index of ≥ 30 kg/m2, is a global epidemic affecting both developed and develop-
ing  countries1. Despite the major progress made in regulating energy balance and understanding the molecular 
mechanisms leading to the development of obesity in both human and animal studies, no safe or effective 
treatment has yet been  found1. Obesity is a chronic disease that is clinically managed by lifestyle modification, 
pharmacotherapy, and surgery. Failure to maintain a healthy body weight has been associated with develop-
ment of chronic diseases such as cardiovascular diseases, type 2 diabetes (T2D) and some forms of  cancer2–4. 
These diseases pose a major health threat as they are considered the top ten leading causes of death  worldwide5. 
Therefore, identification of alternative approaches that can unravel the biochemical and physiological processes 
that occur during development of obesity and progression to chronic diseases are urgently needed. These might 
give insights on obesity and obesity-induced diseases, uncover ways to prevent their development in susceptible 
individuals, and improve on the current treatment strategies.
Serum plays a major role in diagnosis and monitoring of many diseases through immunological assays. Serum 
contains many proteins originating from various tissues and cells within the  body6, and serve as an attractive 
source for biomarker discovery as it can reflect the molecular changes taking place during the development of 
obesity and progression to chronic diseases of  lifestyle7. These proteins can be used as potential biomarkers or 
targets for the targeted treatment of obesity, diagnosis and/or identification of individuals at risk of developing 
obesity-induced diseases. Obesity is a multifaceted disease, as a result a single biomarker cannot entirely describe 
all the pathways affected. Several adipokines, cytokines, metabolites, and microRNAs are implicated in obesity-
induced diseases, some are dysregulated in more than one disease while some show potential as disease-specific 
biomarkers. Their expression levels can identify individuals with or at risk of developing obesity-related diseases 
such as inflammatory  diseases8,  diabetes9,  CVDs10 and metabolically unhealthy obese  people11.
Proteomics has been especially helpful in biomarker discovery for chronic diseases, not limited to  cancer12, 
and  obesity11,13. Proteomics provides a platform to study the entire proteome in a given sample, and allows for 
qualitative and quantitative protein profile that can discriminate between healthy and diseased  samples14. This 
study aimed to use proteomics combined with bioinformatics to identify the serum proteome response to HF 
diet induced obesity in Wistar rats and use in silico analysis to determine potential interactions of the identified 
proteins.
Results
Dietary fatty acid composition. Wistar rats were subjected to LF as a normal diet and three different HF 
diets to induce obesity, distribution of fatty acids (FAs) among the four diets was analyzed by GC MS. The LF diet 
had significantly higher amounts of unsaturated long-chain FA content than the three HF diets as illustrated in 
Table 1. The LF diet contained 75% unsaturated and 25% saturated FAs. In contrast, the HF1-3 diets had higher 
percentage of saturated FAs (56%, 50% and 49%, respectively). The HF3 diet had the highest content of saturated 
FAs, followed by HF1 and HF2. The palmitic acid and stearic acid were the highest saturated FAs in all the HF 
diets. The HF1 diet contained two folds of short chain saturated FAs (8% myristic acid) than the other two HF 
diets and the LF diet. The content of oleic acid was not significantly different across the four diets.
Effects of HF diets on body weight and food intake. A rat model of diet-induced obesity (DIO) was 
initially established by comparing the effects of three HF diets on body weight gain, development of obesity 
and serum proteome expression. As depicted in Fig. 1a, the three HF diet groups gained more weight than the 
LF group throughout the period of the study (8 weeks). The differences in the body weights were noticeable as 
early as the first week on the HF diets when compared to the rats on the LF diet. The HF1 and HF2 diets caused 
more bodyweight gain within 8 weeks than the HF3 diet. The difference between the LF and HF groups was 
statistically significant. A similar trend was observed with the chronic HF feeding (42 weeks) as that in 8 weeks, 
Table 1.  Analysis of FA content in the four diets by GC MS. FA fatty acid, GC MS least squares, LF low fat, HF 
high fat.
Names of fatty acids (FAs) LF diet (%) HF diet 1 (%) HF diet 2 (%) HF diet 3 (%) Type of FAs
α-linoleic acid (18:2) 1 0 0 1 Unsaturated
γ-linoleic acid (18:3) 4 1 1 1 Unsaturated
Arachidic acid (20:0) 1 1 1 1 Saturated
Palmitoleic acid (16:1) 1 1 2 2 Unsaturated
Mysritic acid (14:0) 4 8 3 3 Saturated
Palmitic acid (16:0) 17 32 24 23 Saturated
Stearic acid (18:0) 7 15 22 22 Saturated
Oleic acid (18:1) 27 33 39 37 Unsaturated
Linoleic acid (18:2) 42 9 9 11 Unsaturated
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where rats on the HF1 diet gained significantly more body weight compared to rats on the LF diet after 42 weeks, 
302.7 ± 67.9 g vs. 236.1 ± 11.9 g, respectively (data not shown).
To determine whether obesity (body weight gain) was caused by hyperphagia (increase in food intake), the 
cumulative food intake was assessed. As shown in Fig. 1b, the LF group consumed more food per gram than the 
three HF groups; and this was evident from the third week on their respective diets. Due to caloric density of 
the HF and LF diets (1 g of diet was equivalent to 5.54, 4.01, 3.85 and 2.67 cal for HF1, HF2, HF3 and LF diets, 
respectively), the HF 1 group had higher energy intake followed by HF2, HF3 and LF groups. These calories were 
calculated based on the nutritional information of the diet provided by the supplier using the 4–4-9 formula for 
calories from carbohydrates, protein and fat, respectively.
Fat distribution and adiposity index. The fat pads (inguinal, perirenal, retroperitoneal) contributed a 
significant amount to the total body weight, as shown in Fig. 2. The fat mass was especially higher in the subcuta-
neous and abdominal fat depots of the HF1 (obese) group when compared to the LF (lean) group. No significant 
difference was visually observed between the fat depots of rats on the HF2, HF3 and the LF diets after 8 weeks 
(data not shown).
Figure 1.  Rat body weights (a) and cumulative food intake (b) was measured weekly for 8 weeks during 
induction of obesity. *Represents p < 0.05.
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The adiposity index (calculated as the percentage of the sum of all the white adipose tissue mass in relation 
to the final rat body weight, was significantly higher in the HF1 group compared to the HF2, HF3 and LF groups 
as shown in Fig. 3. The adipose tissue weights for the HF1 group contributed 6.3% whereas HF2 and HF3 con-
tributed 4% and LF contributed 3%, respectively, to the final body weight. The difference between LF, HF2 and 
HF3 were not statistically significant.
Analysis of serum proteome using MS‑based proteomics. In this study, MS-based proteomics was 
used to determine the changes in protein profiles in sera obtained from lean and DIO rats. Serum albumin was 
removed in order to allow the detection of potential biomarkers which could be present in low abundance. 
Depletion of albumin from serum samples by TCA/acetone precipitation resulted in resolution of ~ 80 spots 
in both the albumin-depleted and albumin-containing samples as shown in Fig.  4a,b. Several spots showed 
significant variations between the control and HF groups. Figure 4a,b show representative 2D gel images from 
albumin depleted (supernatant) and albumin-containing (pellet) serum samples of obese rats, respectively. The 
proteins spots that are significantly dysregulated are highlighted by coloured circles, red circles indicate spots 
with altered expression at both 8 and 42 weeks, while the purple circles show altered expression at 8 weeks, and 
the green circles at 42 weeks.
Spot nos. 2, 3, 7 and 8 were found to be up-regulated and Spot nos. 1, 4, 5 and 6 were down-regulated in the 
HF group. Ten spots showed differential expression that was statistically significant in the albumin-containing 
samples (Fig. 4b), and only two of the spots showed expression levels that was ≥ twofold. The identities of the 
selected spots are listed in Table 2. The protein spots 1–4 in the albumin-depleted sample (Fig. 4c) were identified 
by MS as alpha 2-HS glycoprotein (AHSG, Fetuin-A), HPX, CRP, and AMBP, respectively. The two spots (Spot 
no. 7 and 8) in the albumin-containing sample were identified as APOA4 (Fig. 4c). The expression of CRP was 
upregulated, and AHSG was reduced in the HF groups at both 8 and 42 weeks; whilst AMBP showed reduced 
expression only at 8 weeks and no significant difference at 42 weeks. The expressions of HPX and APOA4 were 
significantly upregulated at 8 weeks, and the upregulation of APOA4 persisted up to 42 weeks.
Validation of protein expression. Expression levels of CRP, AHSG and APOA4 were validated by west-
ern blot analysis at baseline (0) and termination (8 and 42 weeks). TFR was used as an internal loading  control15. 
As shown in Fig. 5, the expression levels between LF and HF groups were not statistically different at base-
line (0 weeks), significant changes were observed after HF diet feeding. However, the expression levels of CRP, 
AHSG, and Apo-IV were upregulated in the three HF groups at 8 weeks.
Protein and gene interactions. Network analysis through String database revealed that AHSG and HPX 
are co-expressed with the other four proteins as shown in Fig. 6a,b. CRP does not co-express with AMBP and 
APOA4. The interaction networks between the proteins were based on text-mining and co-expression. Co-
expression of these proteins was evident in humans as well as other organisms (rodents, fish, cows etc.), although 
variations were observed among the different species (Fig.  6c). Highest co-expression in Homo sapiens was 
between AHSG and AMBP, while the other proteins showed minimal co-expression levels.
Although no research has been done to study interactions among the selected proteins, through literature 
these proteins interact strongly with other proteins that are somehow associated with the differentially expressed 
proteins from this study. Albumin (ALB) has been proven to interact with all the proteins except CRP (Fig. 7). The 
expression of these proteins is strongly associated with alpha fetoprotein (AFP), APOA1, APOA2 and fibrinogen 
gamma chain (FGG). Of the five, only APOA1, APOA2 and ALB were also predicted by GeneMANIA software 
(Fig. 8); where their interactions are through co-localization or co-expression. The roles of these proteins in 
obesity and obesity related diseases are unclear, but they might be involved in a coordinated pathway leading to 
the development of obesity and its related conditions.
Figure 3.  Adiposity index among HF and LF groups at 8 weeks. The AI difference was statistically significant 
for the HF 1 group compared to the LF, HF 2 and HF 3 groups. ***p < 0.0001 vs. LF, ∆∆p < 0.01 vs. HF 1.
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Discussion
Predisposition of people to obesity is due to the interaction between genetic and environmental factors. Multiple 
studies have implicated high-calorie diets as the main environmental factor that triggers the development of obe-
sity in genetically susceptible  individuals16,17. Recently, there has been a rise in the number of studies that inves-
tigated the non-genetic, maternally-derived risk factor due to the rise in the prevalence of obesity in early  life18. 
This information is owed to years of research on animal models of obesity, which strongly correlate to human 
obesity. Animal models of DIO mimic some features of human obesity and can be used to decipher obesity 
Figure 4.  Representative 2D gel images from obese rat serum compared to lean rats. 2D gel maps of albumin-
depleted (a) and albumin-containing (b) serum samples. Magnified images of differentially expressed protein 
spots between LF and HF samples (c). The circles indicate spots that were found to be significantly dysregulated 
in the HF group when compared to the LF group.
Table 2.  Protein spots that were differentially expressed in the serum of obese rats.




(kDa) Calculated pI Sample Time (weeks)
Expression 
in HF
1 Alpha 2-HS glycoprotein Q7TP75 68 4.2 Supernatant 8/42 Upregulated
2 Hemopexin Q5BKB4 51.3 7.58 Supernatant 8 Upregulated
3 C-reactive protein A42579 25.5 4.89 Supernatant 8/42 Upregulated
4 Alpha 1 mac-roglobulin Q63041 16.7 6.46 Supernatant 8 Downregulated
7 Apolipoprotein 
AIV Q5BK92 44.5 5.18 Pellet 8/42 Upregulated8
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development and progression in a manner observed in human beings. Moreover, some of the key variables can 
be easily controlled and monitored with high reproducibility unlike in human  studies19,20. The rat model used in 
this study has been reproducible over several experiments and displayed similar features with human  obesity21,22. 
These rats gained body weight after eating the HF diets in just 8 weeks, had increased glucose levels (data not 
shown) and adipose tissue mass (Fig. 3) when compared with the rats fed the LF diet. This model proved to be 
appropriate to study factors responsible for the transition from lean to obese state and could be useful in attempts 
to decipher issues central to obesity development and progression. Literature have shown that 8 weeks of HF diet 
feeding was sufficient to induce obesity and significant differences in the blood proteome profile of  rodents23,24.
Proteomics has become increasingly important in recent years, and this is driven by the hope of finding new 
molecular diagnostic biomarkers and potential therapeutic targets that are disease-specific in biological  samples25. 
Blood is one of the easily accessible samples and a reliable source of disease indicators. Moreover, blood perfuses 
through different tissues and organs within the body, its protein profiles could be reflective of ongoing changes 
occurring within the body in response to physiological and pathological  states26. Characterization of serum 
protein profiles could enable the discovery of reliable disease-specific  biomarkers24, which can then be used in 
diagnosis, prognosis, and monitoring of disease progression. However, serum proteomics is complicated by the 
presence of high abundant proteins (HAPs) which constitute 95% of total protein content which obscure the 
detection of low abundant proteins (LAPs)26,27. The LAPs are made up of several classes of physiologically impor-
tant proteins such as cytokines, chemokines, peptide hormones, and proteolytic fragments of larger  proteins26. 
In order to avoid throwing away biologically important proteins, both the albumin-depleted and albumin-
containing samples were studied. Several proteins were differentially expressed in the HF groups, of which five 
(CRP, AHSG, AMBP, HPX and ApoA4) were significantly dysregulated. At face value and studying the molecular 
functions of these proteins, it does not seem like there is any correlations between the proteins. Their biological 
functions are well documented. ApoA4 is regarded as a satiety signal and controls the food intake and body 
 weight28. It is also involved in lipid transport, and therefore its expression is expected to increase as fat increases 
in the  body29,30. In addition to these classical roles, ApoA4 has been shown to possess anti-atherogenic and anti-
oxidant  properties31. CRP is an acute-phase sensitive marker for systemic  inflammation32,33, infection and tissue 
 damage34. Elevated levels of CRP are common among individuals with both features of insulin resistance, overt 
 T2D35, overweight,  obesity32 and metabolic  syndrome33. The physiological mechanisms linking elevated CRP to 
these disorders are still not clear, but their association is believed to be mediated by the adipose  tissue24. Unfor-
tunately, CRP is part of the nonspecific acute-phase response to many diseases and cannot be used on its own in 
disease  diagnostics34. AHSG (Fetuin-A) is an abundant circulating blood protein that is produced mainly in the 
liver. It has diverse biological functions including regulation of calcium homeostasis and inhibition of insulin-
induced autophosphorylation of the insulin receptor (IR) and IR-tyrosine kinase activity. The Fetuin-A gene has 
been identified as a susceptibility locus for T2D and metabolic  syndrome36. HPX plays a role in recycling of iron 
within the bloodstream, it is an acute phase protein with anti-oxidant properties. The role of HPX in obesity is 
unclear, but it has been shown to be expressed by the adipose tissue and implicated in lipid metabolism. Its action 
in lipogenesis, adipogenesis and adiponectin expression could shed some insights on obesity development and 
 progression37. Expression of AMBP was downregulated in diet-induced obese Sprague–Dawley  rats24. However, 
its role in the development of obesity and progression to obesity-induced diseases is still vague. Therefore, there 
is a need to investigate whether the changes in its expression is due to the development of the disease instead of 
the effect of HF diet consumption.
Figure 5.  Validation of protein expression on the serum samples from lean and obese rats at 8 weeks. CRP, 
AHSG and ApoA4 expression was compared among the four groups by Western blot analysis and quantified by 
Image J software. TFR was used as a loading control. *p < 0.05 vs. LF, ***p < 0.0001, **p < 0.001.The images were 
cropped from the original blots (see Supplementary Data).
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Independent studies have implicated  AMBP24, ApoA4, CRP,  AHSG38 and  HPX23 in DIO and diabetes. APOA4 
was also increased in plasma samples of 10-year-old prepubertal overweight and obese  boys39 an indication that 
there could be a relationship between obesity and altered expression of APOA4. AHSG and CRP expression 
were found to be increased in obese T2D model rats (OLETF rats) at 34 weeks of age when compared to their 
control (LETO rats)38. In this study, AMBP was significantly reduced at 8 weeks, and its expression at 42 weeks 
did not show any statistical significance. This may suggest that AMBP could be useful as an acute or an early 
biomarker for those at risk of developing obesity or other conditions associated with obesity. In a study by Zhao 
and colleagues, AMBP expression was also reduced at 8 weeks24. Differential expression of CRP and HPX, in 
addition to coagulation and complement factors, were also reported in human plasma samples obtained from 
overweight and obese  individuals40. AHSG expression was upregulated in serum samples of stage IV obese breast 
cancer  patients41. Although the blood proteome profiles reported for obese subjects does not entirely represent 
obesity-specific markers, they may be used as predictive biomarkers to identify individuals at risk of developing 
obesity comorbidities. These biomarkers can be used to detect the severity of obesity, from moderate to morbid 
state, and follow their progression to other chronic diseases, and thus serve as a preventative measure. Evidently, 
the available obesity-associated biomarkers, such as cytokines, are involved in other signalling processes and 
which makes it difficult to find molecules that are truly obesity-specific. For instance, leptin and TNF-α are pro-
inflammatory cytokines and their increased expression is an indication of obese patients at higher risk of T2D 
and CVDs. Changes in expression of adiponectin and omentin are also associated with inflammation, CVDs and 
dysregulated glycemic control. CRP, sex hormone-binding globulin, complement factors and apolipoproteins are 
used as weight loss  markers40. Obesity is a multifaceted disease and a risk factor for metabolic and  CVDs2–4. As 
such, proteins identified in this study might be reflective of dysregulated processes, and not artefacts. Moreover, 
Figure 6.  Protein–protein interactions among the differentially expressed proteins. The networks were 
generated in String database show to co-expression between proteins (a, b). Association between the genes are 
based on co-expression of homologs in Homo sapiens and other species (c). Co-expression scores are based on 
RNA expression patterns and protein co-regulation.
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the use of diets that differ in their fat type and fatty acid composition revealed that the serum proteome can be 
modulated differentially by the diet, which supports the gene by environment interactions in the development 
of obesity. It is possible, as a limitation to this study, that other proteins that are differentially expressed in diet-
induced obesity are not picked up due to the sensitivity of the  technique42,43. The use of other techniques such 
as LC/MS/MS could potentially have provided other potential biomarkers that were expressed at low levels. The 
use of 2D PAGE has been reviewed by Abdallah et al.,44, whereby the limitations were mentioned to include 
issues related to reproducibility, poor representation of low abundant proteins, highly acidic/basic proteins, or 
proteins with extreme size or hydrophobicity, and difficulties in automation of the gel-based  technique44. This is 
undoubtedly one of the shortfalls in this study. Nonetheless, the differentially expressed proteins from this study, 
together with their genes, could be useful targets that can help in the prevention of obesity and progression to 
chronic diseases that are associated with obesity. The feasibility of using these proteins as prognostic biomarkers 
was demonstrated in a clinical study of a diet-induced weight loss intervention for 8 weeks followed by weight 
maintenance for 12 months. Plasma protein profile changed and normalized after sustaining 12% of weight loss, 
APOA4, CRP and HPX were among the proteins that were  studied4, which corroborated the findings of this study.
Conclusion
In conclusion, this study showed differential expression of serum proteome in rats fed HF diets compared to 
rats fed LF diet. The reduced expression of AMBP in the HF fed groups during the early development of obesity 
requires further studies. Moreover, in-silico studies showed interactions between the identified proteins, and 
these will be pursued in future studies to elucidate the mechanisms and the roles played by these proteins. This 
will lead to potential therapeutic and preventive strategies to improve the management of obesity-associated 
chronic diseases.
Methods
Animal studies and diets. Male Wistar rats were obtained at weaning from the Primate Unit (South Afri-
can Medical Research Council/ SAMRC, Tygerberg, South Africa). The rats were given standard rodent chow 
(low fat, LF) for two weeks during adaptation to the housing conditions. The animals were then bodyweight 
matched and divided into LF and HF groups. The rats were fed ad libitum on their specific diets with free access 
Figure 7.  Network interactions between the selected proteins. The networks were generated in String database 
and show co-expression between the differentially expressed proteins and other unrelated proteins.
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to fresh water for the duration of the study. The rats were singly caged in a temperature-controlled environment 
at 23 °C, and 12 h light/dark cycle (6:00 am/6:00 pm). The rats were weighed weekly after they started eating their 
respective diets. At termination, all animals were weighed and sacrificed. Various tissues were weighed, collected 
and stored at − 20 °C until further analysis. The use of animals was in line with the SAMRC and ARRIVE guide-
lines that recognize the NC3Rs initiative. All the procedures involving animals were approved by the South Afri-
can Medical Research Council Ethics Committee for Research on Animals (SAMRC-ECRA) Ref: P04/10/021.
Induction of diet‑induced obesity. Two independent studies were conducted. The first study was performed to 
determine the effects of three high-calorie diets on the development of obesity for 8 weeks, and the second study 
was to explore one diet that showed the highest rate of obesity induction for 42 weeks. The composition of the 
four diets was analyzed using Gas chromatography mass spectrometer (GC–MS).
Experiment 1. 28 rats were bodyweight matched into four groups (n = 7 rats/group). One group served as the 
control (LF) group and was fed chow (Epol, South Africa), and the remaining three groups were fed three differ-
ent chow-based HF diets to induce obesity for 8 weeks. Dietary composition of the four diets is shown in Table 3.
Experiment 2. 14 rats were body weight matched into LF and HF groups (n = 7). HF1 diet was used to induce 
obesity in the HF group, whereas the LF group remained on chow. The rats were fed their respective diets for 
42 weeks.
Collection of blood samples. Blood samples were collected at 0, 8 weeks for the first study, as well as 42 weeks 
for the second study. On the day of blood collection for the baseline samples (0 weeks), food was removed for 
4 h in the morning, in order to obtain postprandial state. Rats were lightly anaesthetized with 5% Halothane 
(Safe Life Pharmaceuticals, Sri Lanka), and blood samples (0.5 ml) were collected into Vacutainer serum tubes 
(Becton Dickinson, South Africa) by slightly snipping off the tip of the tail. At 8 and 42 weeks, blood samples 
were collected through a hepatic vein during exsanguination. The blood samples were left at room temperature 
for 30 min, followed by centrifugation at 7 000 rpm for 10 min at 4 °C. The supernatant (serum) was collected 
into new tubes and stored at − 80 °C until further analysis.
Figure 8.  Genetic interactions among the selected proteins in humans. The co-expression and co-localization 
with other genes was observed through GeneMANIA.
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Serum proteomics. Removal of high abundant proteins. The serum samples were precipitated to remove 
albumin following the TCA/acetone protocol described by Chen et  al.,7 with some modifications. Four vol-
umes of 10% TCA/acetone was added to the serum samples and incubated at − 20 °C for 90 min. The samples 
were centrifuged on an Eppendorf Refrigerated Microcentrifuge (Model 5417R, Sigma-Aldrich, MO, USA) at 
14 000 rpm for 15 min at 4 °C. The supernatant was transferred into a new tube and kept on ice. The pellet was 
washed with 0.5 mL cold acetone and incubated for 15 min at − 20 °C, then centrifuged as before. The super-
natants were combined, and 0.5 mL of fresh acetone was added and incubated at − 20 °C for 90 min and cen-
trifuged as above. Both the TCA/acetone precipitated (albumin-depleted) and acetone precipitated (albumin-
containing) pellets were air dried and resuspended in 0.2 mL of solubilization buffer (7 M urea, 2 M thiourea and 
4% CHAPS; Sigma, USA). The protein concentrations were quantified by Bradford assay and the samples were 
stored at − 20 °C until further analysis.
Two‑dimensional gel electrophoresis. Samples containing 100 µg protein were passively rehydrated onto 7 cm 
IPG strips (Bio-Rad, Hercules, CA, USA) with a pH range 4–7 for 12–16 h, followed by isoelectric focusing 
through the three-step protocol: the initial voltage was limited to 250 V for 10 min then increased to 3,500 V 
for 2,800 Vhr, then continued at 3,500 V to 3,700 Vhr. The current was limited to 50 µA per strip at 20 °C. After 
isoelectric focusing, the strips were first equilibrated in equilibration (EQ) buffer containing 2% 1,4-dithiothrei-
tol (Bio-Rad, Hercules, CA, USA) for 15 min, followed by another 15 min equilibration in the EQ buffer con-
taining 2.5% Iodoacetamide (Bio-Rad, Hercules, CA, USA) with shaking. The proteins were resolved on a 10% 
SDS-PAGE for the albumin-containing samples and 12% SDS-PAGE for the albumin-depleted samples. The gels 
were fixed in methanol/acetic acid/water solution (4:1:5) for 2 h, followed by 3 h of staining with 1X Flamingo 
fluorescent stain (Bio-Rad, Hercules, CA, USA).
Quantitative analysis of gel images. The gel images from both the LF and HF groups were scanned on a Molecu-
lar Imager Pharos FX system (Bio-Rad, Hercules, CA, USA). Image analysis including image editing, spot find-
ing, quantitation, and matching, was carried out using Quantity One Software (Bio-Rad) and PD Quest version 
8.0 2-D gel analysis software (Bio-Rad, Hercules, CA, USA). The protein spots were detected by following the 
PD Quest software instructions using the following parameters: horizontal and vertical streaking removal with 
a radius of 33, smoothing by Power Mean filter with kernel size 3 × 3, speckle removal at a sensitivity of 50. The 
densities of protein spots were normalized using the Local Regression Model. The spots were then quantitatively 
compared between LF and HF groups using the approach by Sun et al.43. Protein spots were considered to be dif-
ferentially expressed if the difference between the average of spot densities between the two groups was twofold 
greater or lesser.
In gel proteolysis. The protein spots that were differentially expressed between the LF and HF groups were 
excised from the gels using the EX Quest spot cutter (Bio-Rad, Hercules, CA, USA). The protein spots were 
tryptically digested following the protocol adapted from  Shevchenko42. The Proteomics Analyzer, Voyager DE 
PRO MALDI MS (Applied Biosystems, UK) was used to identify the obtained mass spectra that were searched 
through a Mascot search engine (https ://www.matri xscie nce.com) then queried against the National Centre for 
Biotechnology Information (NCBI) protein database for protein identification.
Western blot analysis. The identities of the differentially expressed proteins were validated by western blotting. 
The protein samples, 20 µg for albumin-depleted sample and 10 µg for albumin-containing sample, were resolved 
on a 12% SDS-PAGE. The proteins were electroblotted onto Hybond-P nitrocellulose membrane (Amersham 
Biosciences, UK). The membranes were incubated overnight at 4 °C with 1:5,000 primary antibodies (Apo A-IV, 
CRP, Fetuin-A and transferrin (TFR); Santa Cruz Biotechnology, TX, USA), washed and incubated with 1:10 000 
secondary antibodies conjugated to horseradish peroxidase for 1 h at room temperature. The membranes were 
developed with LumiGLO Chemiluminescent Substrate System (Whitehead Scientific) then exposed to X-ray 
film (Amersham Biosciences) for 5 min in a dark room. The X-ray films were processed using the X-ray proces-
sor (Agfa, South Africa), and the images were captured using a Digital Camera. Transferrin was used as a loading 
control. The X-ray films were scanned with a Molecular Imager Pharos FX scan. Image analysis including image 
editing and quantitation was carried out using ImageJ Software (National Institute of Health).
Table 3.  dietary composition of LF and HF diets. LF low fat, HF high fat.
% Diet composition
Animal diets
LF HF1 HF2 HF3
Fats 1.30 34.97 19.28 15.25
Protein 25.05 9.86 19.27 20.85
Carbohydrates 66.70 49.97 57.00 59.45
g/g diet 0.93 0.95 0.96 0.96
KJ/g diet 12.73 18.48 16.79 16.10
kcal/g diet 3.04 4.42 4.01 3.85
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Network analysis. Interaction between selected proteins were analysed through String v10.5 (https ://strin g-db.
org) and GeneMANIA (https ://genem ania.org). The following gene codes: APOA4, AMBP, AHSG, CRP and 
HPX were used to determine how these proteins interact with each other at gene and protein levels.
Statistical analysis. The animal body weights were analyzed statistically using one-way analysis of variance 
(ANOVA) followed by Dunnett’s post hoc analysis performed using GraphPad Prism version 5.00 for Windows, 
GraphPad Software, La Jolla Carlifonia USA, www.graph pad.com. The results were presented as means ± SEM. 
Statistical analysis for 2D gel analysis, the comparison between LF and HF groups was assessed using Student’s 
t-test and Boolean analysis sets by the PD Quest software (Bio-Rad, South Africa). The differences were consid-
ered statistically significant at p < 0.05.
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